GlassScriptPhysician profile
Kamran H Imam
NPI 1013495431
$17,875.31
in general payments reported to CMS, 2019-2025
28 companies · $2,630 in 2025
The $2,630 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $340 · 2022: $1,674 · 2023: $12K · 2024: $1,084 · 2025: $2,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $9,999 · Food and Beverage: $5,741 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $9,999.00 |
| Food and Beverage | $5,741.11 |
| Education | $121.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $10,965.85 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,310.07 | 2021-2025 | Tezspire, Fasenra, Breztri |
| Regeneron Pharmaceuticals, INC. | $1,000.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $593.91 | 2022-2025 | Dupixent |
| Genzyme Corporation | $554.72 | 2022-2025 | |
| Csl Behring | $466.04 | 2021-2025 | Hizentra, Andembry, Haegarda |
| Pharming Healthcare, INC. | $460.87 | 2021-2025 | Ruconest |
| Genentech USA, INC. | $424.45 | 2023-2025 | Xolair |
| Biocryst US Sales Co., LLC | $421.48 | 2023-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $259.51 | 2025 | |
| Grifols USA, LLC | $230.50 | 2022-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $222.95 | 2021-2025 | Takhzyro, Cuvitru |
| Horizon Therapeutics Plc | $115.04 | 2023 | Actimmune |
| Genentech, INC. | $109.29 | 2023 | Xolair |
| Sanofi-Aventis U.S. LLC | $98.99 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $89.78 | 2023 | Vtama |
| Teva Pharmaceuticals USA, INC. | $77.00 | 2023 | Proair Digihaler |
| Ionis Pharmaceuticals, INC. | $75.67 | 2025 | Dawnzera |
| Alk-Abello, INC | $71.12 | 2023-2025 | Ragwitek, Grastek, Odactra |
| Kaleo, INC. | $52.79 | 2022-2023 | Auvi-Q |
| Amgen INC. | $52.74 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.99 | 2022 | |
| Blueprint Medicines Corporation | $47.89 | 2023 | Ayvakit |
| Incyte Corporation | $33.25 | 2022 | |
| Mylan Specialty L.P. | $24.00 | 2024 | Yupelri |
| Abbvie INC. | $23.41 | 2023 | |
| Lilly USA, LLC | $22.70 | 2022 | |
| Cycle Pharmaceuticals INC | $21.30 | 2025 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamran Imam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.